FindTrial
Sign In

Analysis of cytokine and lymphocyte subpopulation levels and clinical anti-tuberculosis efficacy in patients with pulmonary tuberculosis with diabetes mellitus

Analysis of cytokine and lymphocyte subpopulation levels and clinical anti-tuberculosis efficacy in patients with pulmonary tuberculosis with diabetes mellitus

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080699
Enrollment
Unknown
Registered
2024-02-05
Start date
2024-02-16
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis

Interventions

tuberculosis patients with diabetes group:None
tuberculosis patients without diabetes co-morbidity:None

Sponsors

Zhejiang Qingchun Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 Between January 2020 and July 2022, TB patients 2. age =18 3. No evidence for treatment resistance

Exclusion criteria

Exclusion criteria: 1. Patients suffering any severe somatic disorder such as heart failure, chronic obstructive pulmonary disease (COPD), liver cirrhosis, chronic kidney disease, neoplasm or immunological deficiency were excluded. 2. Subjects with a previous history of resistance were also excluded, as were pregnant or breastfeeding women 3. Patients who refused informed consent

Design outcomes

Primary

MeasureTime frame
Interleukin 6, interleukin 8, tumor necrosis factor;outcome;—

Countries

China

Contacts

Public ContactFengjun Tong

Zhejiang Qingchun Hospital

923299209@qq.com+86 137 0571 3515

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026